Introduction. Hypovitaminosis D affects one-third to two-thirds of children and pregnant women from the Middle East and North Africa (MENA) region.
Introduction
Hypovitaminosis D is a global public health problem, affecting children, adults and elderly [1] . In the Middle East and North Africa (MENA) region, 30%-75% of children have a 25-hydroxyvitamin D [25(OH)D] level less than 20 ng/ml [2] , the desirable level set by the National Academy of Medicine (NAM) [Institute Of Medicine (IOM)] [3] . Such findings are close to those reported in US children [4] . In pregnant women, a systematic review of 18 observational studies showed that, during the first trimester, mean 25(OH)D level ranged between 11 ng/ml and 29 ng/ml in Caucasians, and 6 ng/ml and 17 ng/ml, in non-Caucasians, including Turkish, Moroccan, and other non-Western women [5] . Another recent systematic review comparing maternal and neonatal vitamin D status in different regions worldwide, showed that the prevalence of a 25(OH)D of < 20 ng/ml is 46% and 60% in Middle Eastern pregnant women and their neonates, respectively [6] . In addition to the well-known risk factors for vitamin D deficiency in adults, including older age, female gender, higher latitude, and dark skin pigmentation, other risk factors specific to the MENA region have been identified [2] .
Multiparity, veiling of women, the winter season in the Mediterranean countries and the summer in gulf countries, low socio-economic and educational status, urban living, low dietary vitamin D intake, and genetic polymorphism of vitamin D metabolizing enzymes, have been identified as significant predictors of hypovitaminosis D [2] . Vitamin D was traditionally labeled as an important factor for bone formation and regulation of mineral hemostasis in infants and children [7] . Vitamin D deficiency in the pediatric population results in the development of rickets, characterized by hypocalcemia, growth retardation and long bones deformities [7, 8] . In addition, the potential extra-skeletal consequences of vitamin D deficiency were illustrated in several observational studies conducted in children, whereby hypovitaminosis D was associated with an increased risk of asthma, infections and auto-immune diseases, specifically type 1 diabetes [4, 9] .
Pregnant women represent another vulnerable population, in whom hypovitaminosis is associated with adverse outcomes, such as gestational diabetes mellitus (GDM), preeclampsia, C-section and bacterial vaginosis [10] . Vitamin D deficiency affects not only the mothers, but also their offsprings [10] . Maternal 25(OH)D levels directly correlate with venous cord 25(OH)D levels [11] . Indeed, vitamin D plays a significant role in the development of fetal bone and muscle mass [12, 13] . Maternal hypovitaminosis D is associated with neonatal complications, including preterm birth and small for gestational age [14] , in addition to long term complications, such as a reduced bone mass in children at 4 and 9 years [13, 15] .
Vitamin D replacement guidelines in infants, children and adolescents differ between societies (Appendix 1A). The NAM (IOM) recommends in infants 400 IU/d (as adequate intake), and 600 IU/d in children and adolescents [as the Recommended Dietary Allowance (RDA)], allowing to 97.5% of the population to reach a target 25(OH)D level of 20 ng/ml [3] . The Endocrine Society (ES) recommends higher doses, of 400-1000 IU/d in infants and 600-1000 IU/d in children and adolescents, aiming at a desirable level of 30 ng/ml [16] . Similarly, vitamin D replacement guidelines in pregnant women vary widely (Appendix 1A). While the NAM (IOM) recommends 600 IU/d to reach the target 25(OH)D level of 20 ng/ml [3] , the ES recommends 1500-2000 IU/d to reach a 25(OH)D level of 30 ng/ml [16] . Conversely, the WHO recommends no supplementation unless the pregnant woman has a dark skin or is from a population with a high prevalence of vitamin D deficiency [17] . Noteworthy that all these guidelines have been derived from studies conducted in Western populations and may not be applicable to the MENA region, where vitamin D deficiency is prevalent [2] .
The objectives of this paper are to evaluate the following, in infants, children, adolescents and pregnant women, from the MENA region:
(1) The mean difference in 25 Findings from this systematic review will guide region specific recommendations on vitamin D replacement in infants, children, adolescents and pregnant women.
Methods
The protocol of this systematic review is available online on PROSPERO; registration number CRD42014010488 [18] . [18, 20] ).
Exclusion Criteria
We excluded studies conducted in children with rickets, in institutionalized/hospitalized individuals, those with chronic illnesses (kidney, liver or heart failure), and in the presence of conditions or drug therapy that affect vitamin D metabolism (malabsorption, anticonvulsants, steroids, antifungal medications). We excluded also studies administering vitamin D supplementation as a fortified food or in the active form.
Search Strategy
We conducted a comprehensive literature search until 2015 and a search update in November 2016, in seven electronic databases: Medline, Embase, PubMed, Cochrane Library, in addition to Popline, Index Medicus for WHO Eastern Mediterranean Region (IMEMR), and Global Health Library, without time or language restriction. We used MeSH terms and keywords related to Vitamin D and MENA countries, and we applied an RCT filter [18, 20] . We identified additional trials by searching trial registries, including the ClinicalTrial.gov., and the WHO International Clinical Trials Registry (ICTRP), and by screening the references lists of recent systematic reviews on vitamin D trials.
Study Selection
Teams of two reviewers (MC, SEG, KS) screened the titles and abstracts of all the retrieved citations, in duplicate, and independently. We obtained the full texts of references judged as potentially eligible by at least one reviewer. Similarly, we screened the full text of retained articles independently for eligibility. We resolved disagreements by discussion or with the help of a content expert (GEHF). In order to standardize the screening methodology, we conducted a calibration exercise on a sample of abstracts and full articles.
Data Collection
We prepared data collection forms a priori and pilot tested them, in duplicate and independently. 
Risk of Bias Assessment
We assessed in duplicate and independently the risk of bias for the primary outcome, the mean difference in 25(OH)D level achieved following the intervention, in the included studies using the Cochrane Collaboration's tool for bias assessment [21] . This tool includes 5 domains, and these are: sequence generation, allocation concealment, blinding, incomplete outcome data and selective outcome reporting [21] . We resolved disagreement by discussion with experts (GEHF, EA). [20] ). Such variables allow to compare results in different dose categories. Using the aforementioned weighted means and Sdp, and assuming normality of the distribution of 25(OH)D level, we calculated the proportion (%), and 95% CI, of subjects reaching a 25(OH)D ≥ 20 ng/ml, at the end of the intervention in each dose category. We calculated 95% CI of the proportions using an online calculator [22] . In case of missing data, we based our analysis on a complete case scenario (excluding participants for whom data were missing). We assessed statistical heterogeneity between studies using the I 2 and chi square, with significance at a p-value ≤0.05.
Results
The search strategy yielded 4949 citations. 4690 citations were excluded and 259 full text articles were assessed for eligibility. We excluded 244 articles for various reasons, as detailed in Fig. 1 diagram. We included 10 studies in pregnant women, 4 in children and adolescents and one study in infants.
Effect of Vitamin D Replacement on 25(OH)D Level

Infants
We identified only one trial in infants from Iran, comparing 2 low doses of vitamin D, 400 IU versus 200 IU daily, administered in drops, and foodlet or sprinkles, respectively [23] . The baseline 25(OH)D level was 82-88.9 ng/ml (Table 1, Appendix 2). At the end of the study, 25(OH)D level was significantly higher in the group that received drops, 96.4(32.1) ng/ml, versus 88.5(28.4) ng/ml and 87.4(32) ng/ml, in the groups that received foodlet and sprinkles, respectively [23] . 25(OH)D level was measured using a radioimmunoassay.
Children and Adolescents
We identified 4 studies conducted in children and adolescents [24] [25] [26] [27] [28] . Two studies were from Iran [27, 28] , one study from Lebanon [24] and one study from Israel [26] . The four studies were conducted in healthy school children, girls and boys, and the range of mean age of participants was 9.8-16.6 years. The baseline mean 25(OH)D level ranged between 7.9 and 25 ng/ml (Table 1, Appendix 2). The vitamin D assay used was high pressure liquid chromatography (HPLC) in one study [28] , and immune-assays were used in the other three [24, 26, 27] . Concomitant calcium supplementation was administered in one study [28] . Compliance to vitamin D supplementation was described in one study only, ranging between 97 and 98% in the low, intermediate, and placebo arms [24] . The reported rates of loss to follow-up were less than 15% in three studies [24, 27, 28] , and no loss to follow-up was reported in one study [26] . The risk of bias assessed by the Cochrane Tool was judged as high in the trial by Neyestani et al. [28] (mostly related to inadequate allocation concealment and performance bias), unclear in the trials by Ghazi et al. [27] and Mayan et al. [26] , and low in the trial by El Hajj Fuleihan et al. [24, 25] , respectively ( [24, 25] extended over 12 months, the one by Ghazi et al. [27] extended over 6 months, and the study by Mayan et al. [26] extended over 3 months (Table 1 [24, 25, 28] (Table 1 , Appendix 2). The total number of participants was 174 in the low dose group, and 164 in the placebo group. The WM baseline 25(OH)D was 13.4 ng/ml. There was no significant difference in the achieved 25(OH)D level between the low dose and placebo (Fig. 3B ).
Pregnant Women
We identified 10 eligible studies conducted in pregnant women [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] (Table 1 , Appendix 2). Nine studies were from Iran and one study was from UAE. Five studies were conducted in healthy pregnant women, while the others were conducted in women with multiple sclerosis (MS) [33] , at risk of preeclampsia [34, 35] , gestational diabetes mellitus [36] , or recurrent unexplained abortions [38] . The mean BMI of participants varied between 25 and 28.7 kg/m 2 . Only one study administered calcium supplementation as part of the intervention [35] . Vitamin D supplementation was started at 12-20 weeks of gestation, with the exception of two studies, where vitamin D supplementation was started at 26-28 weeks of gestation [29, 37] , and another one where supplementation started as soon as pregnancy was confirmed by abdominal US and βhCG level [38] (Table 1 , Appendix 2). All studies administered vitamin D until delivery, except the trials by Karamali et al. [34] , Shahgheibi et al. [36] and Samimi et al. [38] where supplementation was stopped in the third trimester. In four trials comparing a high dose to placebo, all participants received additional vitamin D supplementation of 200-400 IU daily [30, 34, 35, 37] . Therefore, the control arms in these studies were considered as administering a low vitamin D dose [30, 34, 35, 37] . Maternal 25(OH)D level at delivery was reported in five studies, one of them reported also results on venous cord 25(OH)D level [29] . Etemadifar and Janghorbani [33] reported maternal 25(OH)D levels at 6 months post-partum and not at delivery. In the trial assessing the effect of vitamin D on unexplained recurrent abortions, Samimi et al. [38] reported 25(OH)D level at 20 weeks' gestation, rather than at delivery. Shakiba and Iranmanesh [31] reported only on 25(OH)D levels in venous cord blood. Karamali et al. [34] assessed 25(OH)D levels at 32 weeks' gestation. The achieved 25(OH)D level following the intervention was missing in one of the studies [36] . The vitamin D assays used were variable and none of the studies used the accurate method HPLC. Compliance rate was described in 3 studies only. Dawodu et al. [30] reported a compliance rate of 86% in the high dose arm, 87% in the intermediate arm, and 82% in the low dose arm. Karamali et al. [34] reported a 100% compliance rate in both groups. Samimi et al. [35] reported a compliance >90% in the study assessing the effect of vitamin D supplementation during pregnancy on metabolic profile. Vaziri et al. [37] excluded participants who were not compliant. A very high proportion of participants were lost to follow-up in one trial, ranging between 59% and 71% [33] . In the remaining studies, the loss to follow-up varied between 0 and 20%. The risk of bias assessment showed that two studies were at low risk of bias across all domains [34, 35] . Two studies were open label, and thus at high risk of selection and performance bias [32, 33] . The remaining studies were rated as having unclear risk of bias because they did not describe any details related to sequence generation, allocation concealment, blinding and/or incomplete outcome data (Fig. 2B , Appendix 3A).
3.1.3.1. Vitamin D Low Dose (< 800 IU/d) Versus Placebo. We identified two studies in this category [36, 38] . Samimi et al. [38] administered 400 IU/d vitamin D to deficient pregnant women early in their first trimester and assessed response at 20 weeks' gestation. Shahgheibi et al. [36] started vitamin D supplementation in the first trimester until 26 weeks' gestation. The latter study did not report on the achieved 25(OH)D levels at the end of the intervention [36] . Therefore, we were not able to conduct a meta-analysis in this comparison. 2) ng/ml, favoring the high dose, p < 0.001, with high heterogeneity (I 2 95%, p < 0.001) (Fig. 4C) . The calculated weighted mean baseline 25(OH)D level was 12.2 and 11 ng/ml, in the low and high dose arms, respectively. The calculated weighted mean 25(OH)D level achieved postintervention was 27.9 (Sdp = 9.4) ng/ml in the high dose group and 15.9 (Sdp = 6.7) ng/ml in the low dose group. The proportions of subjects who reach the target 25(OH)D of 20 ng/ml were 80% in the high dose group and 27% in the low dose group. Aiming at a target 25(OH)D level of 30 ng/ml, the proportion of pregnant women would be 40% and 1.7% in the high and low dose groups, respectively (Table 2) . A sensitivity analysis in the high versus low dose comparison, including only the studies with low risk of bias [30, 34, 35] , showed an MD in 25(OH)D level of 13.1 (95% CI 5.4-20.7) ng/ml, favoring the high dose, with high heterogeneity (I 2 95%, p < 0.001).
3. 
Effect of Vitamin D Replacement on Other Outcomes
Children and Adolescents
The effect of vitamin D supplementation on PTH level was assessed in children and adolescents. While an intermediate dose (weighted mean dose of 1870 IU/d), significantly reduced PTH level, compared to placebo, with an MD in PTH level achieved of −7.0 (95% CI −7.4 to −6.6) pg/ml, a low dose did not have any effect on PTH levels. The effect of an intermediate dose of vitamin D on serum calcium level was not significant (Table 3A) . 
Pregnant Women
The effect of vitamin D supplementation on serum calcium level was assessed in trials conducted in pregnant women. The MD in serum calcium level achieved across various comparisons did not reach statistical significance, except in the high versus low dose comparison, whereby the serum calcium level was lower in the high dose group, compared to the low dose by the end of the intervention, with a drop by 0.05 mg/dl (Table 3B) . Three studies, comparing a high versus low vitamin D dose, assessed the effect of supplementation on glycemic indices, and showed a significant decrease in fasting blood glucose (a drop by 3 mg/dl), in HOMA-IR (a drop by 1.5), and in insulin levels (a drop by 6.7 IU/ml), favoring the high dose group [32, 34, 37] . Two studies assessed the effect of a high vitamin D dose compared to a low dose on lipid profile and inflammatory markers (hs-CRP). A high vitamin D dose resulted in a significant increase in HDL level (by 4.1 mg/dl), a significant decrease in hs-CRP (by 1350.7 ng/ml) and a decrease in diastolic blood pressure (by − 3.5 mm Hg) (Table 3B ).
Vitamin D Dose Response
We could not assess the vitamin D dose response, given the small number of studies included in each comparison.
Discussion
In children and adolescents, an intermediate vitamin D dose (~1900 IU daily) increased the weighted mean 25(OH)D level [30] and Soheilykhah et al. [32] ). Vitamin D supplementation started at 20 weeks' gestation and continued until 32 weeks' gestation in 2 other studies (Karamali et al. [34] and Samimi et al. [35] ). The study by Vaziri et al. [37] The trial by El Hajj Fuleihan was the only one to assess the effect of vitamin D supplementation on musculo-skeletal parameters in children and adolescents [24, 25] . While supplementation in boys did not yield any significant effect [42] , low and high vitamin D doses resulted in a significant 
Outcome
Result Studies included improvement in lean mass and total hip bone mineral content (BMC) in girls [24] ; interestingly, this effect persisted after 1 year of discontinuation of trial supplementation [43] . Bone specific alkaline phosphatase (BAP) was assessed in 2 studies in children and adolescents [27, 28] , falling into 2 different comparisons. Therefore, we were not able to pool their results. Both studies showed a trend toward an increase in BAP by the end of the intervention [27, 28] . Similar changes were reported in the osteocalcin level [27, 28] . El Hajj Fuleihan assessed alkaline phosphatase and showed a decrease in the level by the end of the intervention (a decrease by 17%-24% in girls, and 10%-11.7% in boys, but not-significantly different from placebo) [24, 25] . Ghazi et al. [27] [45] . The estimated proportions of women reaching the target level of 20 ng/ml were 78%, 92%, 93%, in the aforementioned doses, respectively. Another three-arm study (600, 1200 and 2000 IU/d) from Turkey started at a lower baseline 25(OH)D of 9.9-11 ng/ml, the highest dose allowed for 80% of pregnant women to reach the target level of 20 ng/ml, while the other doses allowed less than 50% of the participants to do so [46] [48] . Unfortunately, we could not compare these findings to ours, since our comparisons in pregnant women did not include a placebo arm.
In the MENA region, data on the effect of vitamin D supplementation on other neonatal and maternal skeletal outcomes are scarce. There are no fracture data, and one study only assessed the effect of vitamin D supplementation on maternal and neonatal bone density and did not detect any significant difference between the high and the low dose groups [37, 49] . Similarly, there was no significant effect of a high vitamin D on neonatal and infant anthropometric measures [30, 35, 49] . These findings replicate the results of a large randomized controlled trial in UK, comparing a daily vitamin D dose of 1000 IU to placebo [44] . None of the studies conducted in pregnant women reported on changes in bone markers.
Four trials assessed the effect of vitamin D replacement during pregnancy on metabolic outcomes. A high vitamin D dose compared to a low dose resulted in a significant reduction in glycemic and inflammatory indices ( Table 2) .
Our results show that the vitamin D doses needed to reach desirable levels in the MENA region seem higher compared to the doses recommended by the NAM (IOM) for Northern America and Canada [3, 16, 50] . The prevalence of hypovitaminosis D is the highest in the MENA, compared to other Western countries [1, 51] . Several specific risk factors for hypovitaminosis D have been described in our region, including low intake of vitamin D fortified food, veiling, low socio-economic status, genetic polymorphism of metabolizing enzymes, implying lower baseline vitamin D status and potentially higher vitamin D requirements. Whether genetic and environmental factors affect the response to vitamin D supplementation still needs to be confirmed.
Strengths and Limitations
This is the first systematic review of vitamin D RCTs in children, adolescents and pregnant women, conducted in the MENA region, based on an extensive search in 7 databases. It identifies the available evidence and describes knowledge gaps revolving around this topic. Our review suffers from several limitations, in large part due to the nature of the studies and the data available. There were a limited number of studies identified in the pediatric group. We identified a single study in infants and 4 studies in children and adolescents. Findings in children and adolescents showed high heterogeneity, related to variability in several factors, including age, duration of supplementation, vitamin D assays used, to name few. The majority of included studies in all categories were conducted in Iran (2/4 in children and adolescents; 9/10 in pregnant women), and therefore, the derived results are not generalizable to other MENA countries. The effect of vitamin D supplementation on skeletal and extra-skeletal outcomes was poorly assessed, and when done, only surrogate outcomes were evaluated. In pregnant women, findings on the metabolic effects of vitamin D supplementation were derived from 3 studies, 2 of them were conducted by the same research group, with a very similar profile of the enrolled participants. There was a large variability in the vitamin D assays used, and this could have significantly affected the results. Data on the safety of high doses in the pediatric population are still lacking, since none of the studies identified used a high dose. In pregnancy, although all the included studies administered a high dose, reporting of adverse events was inconsistent, and available only in half of them.
Conclusion
In 
